Antifungal Resistance and Its Implications in the Management of Mold Infections - Enduring

In the last few decades there has been an issue of increased antifungal use - both in the increasingly vulnerable immunocompromised patients and in the environment, for agriculture purposes: de novo resistance in the fungi (especially molds) at the time of infection and secondarily in the patient upon exposure to antifungal drugs. To address this topic, it is imperative to provide the most current updates in mycology in order to bridge any gaps in knowledge.

This activity is necessary for City of Hope clinicians, as they manage highly immunocompromised patients with cancer, especially those with hematologic malignancies and stem cell transplantation. They manage an increasingly complex patient population, with many patients having refractory disease requiring prolonged courses of antifungal putting them at high risk for resistant fungal infections. An expert at the forefront of bench research in mycology will provide information on the basic biology of resistance and interventions. 

Target Audience

Physician faculty and APP in hematology/HCT who actively provide treatment to such patients.

Learning Objectives

  • Identify risk factors for antifungal resistance in molds.
  • Appreciate the mechanism of resistance.
  • Evaluate for antifungal resistance and interpret data. 
  • Assess antifungal management.
  • Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Activity summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Antifungal Resistance and Its Implications in the Management of Mold Infections - Enduring for a maximum of 1.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Attendance
Activity opens: 
08/01/2022
Activity expires: 
12/12/2023
Internet
United States

This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.

As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 24 months. Faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships with any ineligible company, which is defined as any entity whose primary business is to produce, market , sell, re-sell or distribute healthcare products used by or on patients. To comply with more intense scrutiny by accreditation agencies, content whose faculty has disclosed any relevant financial relationships with an ineligible company, have been peer reviewed prior to presenting and any potential conflicts relative to the previous disclosure have been resolved.

Presenter: Dr. Thomas J. Walsh has indicated the following relevant financial relationships: Grant/Research Support from Amplyx, Astellas, Merck, Scynexis, T2 Biosystems and Tetraphase; is a Consultant for Amplyx, Astellas, ContraFect, Gilead, Merck, Methylgene, Partner Therapeutics, Pfizer, Scynexis and T2 Biosystems. 

The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.

CME Committee/Reviewer Nothing to Disclose:  Patricia Aoun, MD; Chandana Banerjee, MD; Daneng Li, MD; Anna Pawlowska, MD; Michael Rosenzweig, MD; Crystal Saavedra; Behrouz Salehian, MD; Gagandeep Singh, MD; Sepidah Shayani, PharmD; Shanmuga Subbiah, MD

City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.

The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.

This activity has received no commercial support.

ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The following credit type(s) are being offered for this course:

•  AMA PRA Category 1 Credit™  1.25

The following may apply AMA PRA Category 1 Credit™ for license renewal:

Registered Nurses: Nurses may report up to 1.25 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.

Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
 

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
    City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
    City of Hope designates this Antifungal Resistance and Its Implications in the Management of Mold Infections - Enduring for a maximum of 1.25 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.25 Attendance
Please login or register to take this activity.

You must be logged in to access this Enduring. 

If you are a New User, please create an account first, by clicking on "Register". 

Once Logged in: 

Click on "Start Activity" to access the educational content for this Enduring activity.


ACTIVITY INSTRUCTIONS

In order to earn credit for this activity, participants must:

  • Read learning objectives and faculty disclosures
  • View Enduring Activity Video
  • Complete the evaluation

Upon satisfactory completion, you will have the option to receive a print out of your certificate.

If you have questions regarding this process, please contact the City of Hope Continuing Medical Education at 626-218-5622 or cme@coh.org

Estimated timeframe for completion of this activity, including the time to complete the evaluation is 1 hour 15 minutes.

Required Hardware/software

Current version of Edge, Firefox, Safari, or Chrome.